Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Kamada AAT for · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Alpha-1 Antitrypsin | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Kamada AAT for inhalation | BIOLOGICAL | Alpha-1 Antitrypsin (AAT) |
| Placebo | OTHER | Placebo |
Principal Inclusion Criteria: * Diagnosis of emphysema confirmed by CT scan. If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening * Male or female patients at least 18 years of age. * Able and willing to sign an informed consent. * Patient ...
Kamada AAT for is an inhaled, human, alpha-1 antitrypsin (AAT) therapy in Phase 2 clinical development for the treatment of Alpha-1 Antitrypsin Deficiency and emphysema. It is being developed by Kamada Ltd. (KMDA) as a respiratory therapeutic. The drug is administered via inhalation to deliver AAT directly to the lungs.
Kamada AAT for is a monoclonal antibody that targets alpha-1 antitrypsin deficiency, a genetic condition that leads to low levels of the AAT protein, which protects the lungs from damage. By delivering inhaled human AAT, the therapy aims to supplement the deficient protein and potentially slow the progression of emphysema associated with the condition.
Kamada AAT for is developed by Kamada Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KMDA. The company specializes in plasma-derived therapies and is conducting clinical trials to evaluate the safety and efficacy of this inhaled AAT product for patients with Alpha-1 Antitrypsin Deficiency and emphysema.
Kamada AAT for is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 clinical trials have been completed, with a total enrollment of 204 patients across studies in multiple countries, including the United States, Canada, and several European nations.
Kamada AAT for has been studied in two completed Phase 2 clinical trials. The first, NCT01217671, enrolled 168 patients with emphysema across Canada, Denmark, Germany, Ireland, Netherlands, Sweden, and the United Kingdom. The second, NCT02001688, enrolled 36 patients with Alpha-1 Antitrypsin Deficiency in the United States. Both trials were randomized, double-blind, and placebo-controlled.
Yes, Kamada AAT for is the same drug as Kamada-alpha-1-antitrypsin (AAT) for inhalation. The clinical trial NCT02001688 refers to the drug as Kamada-alpha-1-antitrypsin (AAT) for inhalation, while the product is commonly known as Kamada AAT for. Both names refer to the same inhaled human AAT therapy under development by Kamada Ltd.